Detection across tumor types supports the use of next-generation sequencing.
Basket trials are those that test investigational therapies in patients who have different types of cancer but share a particular genomic aberration.
Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows.
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients.
This study used comprehensive microarray analysis of serum to identify a panel of 7 miRNAs specific to sarcoma.
With the rising rates of cancer diagnosis and increasing cost of treatment, delays in time to treatment initiation can be seen as primarily policy related.
The study showed little value for the molecular assay in improving outcomes, but several weaknesses may have undermined the investigation.
Some chemotherapeutic drugs have been shown to stimulate the immune system, despite the historical belief that chemotherapies are immunosuppressive.